Trial Condition(s):

Macular degeneration

EYLEA Age-Related Macular Degeneration (AMD) post-marketing surveillance in Japan

Bayer Identifier:

15895

ClinicalTrials.gov Identifier:

NCT01756248

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).
The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice.
A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.

Inclusion Criteria
- Patients who received EYLEA for AMD
Exclusion Criteria
- Patients who have already received EYLEA

Trial Summary

Enrollment Goal
3872
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Active, not recruiting
 

Trial Design